skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

Review

(2317) Views  (961) Full article downloads

Authors: Barbara P Yawn, Ibrahim Raphiou, Judith S Hurley, et al

Published Date June 2010 Volume 2010:5 Pages 165 - 178
DOI: http://dx.doi.org/10.2147/COPD.S4159

Barbara P Yawn1, Ibrahim Raphiou2, Judith S Hurley3, Anand A Dalal2

1Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA; 2GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 3Hurley Consulting, Placitas, New Mexico, USA

Abstract: Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 μg) and the long-acting β2-agonist salmeterol (50 μg) in a single inhaler (250/50 μg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results of various studies suggest that fluticasone propionate and salmeterol have synergistic effects when administered together that improve their efficacy in controlling symptoms and reducing exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.

Keywords: Advair, COPD, disease exacerbation, fluticasone propionate, salmeterol, combination drug therapy






 

Other articles by Dr Anand Dalal

Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population
Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
Direct costs of chronic obstructive pulmonary disease among managed care patients
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims
Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history
  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio